NCT03983954 2025-11-28Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.NeoTX Therapeutics Ltd.Phase 1 Active not recruiting120 enrolled
NCT04272034 2025-10-16Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid TumorsIncyte CorporationPhase 1 Terminated105 enrolled
NCT02628067 2025-09-22KEYNOTE 158Merck Sharp & Dohme LLCPhase 2 Active not recruiting1,609 enrolled 5 FDA
NCT03126110 2025-08-14Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic MalignanciesIncyte CorporationPhase 1/2 Completed145 enrolled 47 charts
NCT06299163 2025-07-23NM32-2668 in Adult Patients With Selected Advanced Solid TumorsNumab Therapeutics AGPhase 1 Terminated11 enrolled
NCT05714553 2025-07-18NUC-3373 in Combination With Other Agents in Patients With Advanced Solid TumoursNuCana plcPhase 1/2 Terminated19 enrolled
NCT02611024 2025-07-09Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid TumorsPharmaMarPhase 1/2 Completed316 enrolled
NCT04104776 2025-05-15A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasNovartisPhase 1/2 Recruiting275 enrolled